Literature DB >> 17032919

Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia.

Rosemarijn Renckens1, Joris J T H Roelofs, Peter I Bonta, Sandrine Florquin, Carlie J M de Vries, Marcel Levi, Peter Carmeliet, Cornelis van't Veer, Tom van der Poll.   

Abstract

Plasminogen activator inhibitor type-1 (PAI-1) levels are consistently elevated in patients with severe pneumonia and sepsis and highly predictive for an unfavorable outcome. In addition, pneumonia is associated with strongly elevated PAI-1 levels in the pulmonary compartment. However, whether PAI-1 causally affects antibacterial host defense in vivo remains unknown. We report here that pneumonia caused by the common respiratory pathogen Klebsiella pneumoniae is associated with local production of PAI-1 in the lungs of wild-type mice. PAI-1 deficiency impaired host defense as reflected by enhanced lethality and increased bacterial growth and dissemination in mice with a targeted deletion of the PAI-1 gene. Conversely, transgenic overexpression of PAI-1 in the lung using a replication-defective adenoviral vector markedly improved host defense against Klebsiella pneumonia and sepsis. PAI-1 deficiency reduced accumulation of neutrophils in the lungs during pneumonia, whereas PAI-1 overexpression in healthy lungs resulted in neutrophil influx, suggesting that PAI-1 protects the host against Klebsiella pneumonia by promoting neutrophil recruitment to the pulmonary compartment. These data demonstrate for the first time that PAI-1 is essential for host defense against severe Gram-negative pneumonia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17032919     DOI: 10.1182/blood-2006-05-025197

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  Interleukin-1 receptor-associated kinase M-deficient mice demonstrate an improved host defense during Gram-negative pneumonia.

Authors:  Jacobien J Hoogerwerf; Gerritje J W van der Windt; Dana C Blok; Arie J Hoogendijk; Alex F De Vos; Cornelis van 't Veer; Sandrine Florquin; Koichi S Kobayashi; Richard A Flavell; Tom van der Poll
Journal:  Mol Med       Date:  2012-09-25       Impact factor: 6.354

2.  Kinase activity profiling of gram-negative pneumonia.

Authors:  Arie J Hoogendijk; Sander H Diks; Maikel P Peppelenbosch; Tom Van Der Poll; Catharina W Wieland
Journal:  Mol Med       Date:  2011-03-15       Impact factor: 6.354

3.  Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica.

Authors:  Deyan Luo; Frank M Szaba; Lawrence W Kummer; Edward F Plow; Nigel Mackman; David Gailani; Stephen T Smiley
Journal:  J Immunol       Date:  2011-07-01       Impact factor: 5.422

4.  Critical role of type 1 plasminogen activator inhibitor (PAI-1) in early host defense against nontypeable Haemophilus influenzae (NTHi) infection.

Authors:  Jae Hyang Lim; Chang-Hoon Woo; Jian-Dong Li
Journal:  Biochem Biophys Res Commun       Date:  2011-09-14       Impact factor: 3.575

5.  Plasminogen activator inhibitor-1 regulates LPS-induced TLR4/MD-2 pathway activation and inflammation in alveolar macrophages.

Authors:  Weiying Ren; Zhonghui Wang; Feng Hua; Lei Zhu
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

6.  PAI-1 is an essential component of the pulmonary host response during Pseudomonas aeruginosa pneumonia in mice.

Authors:  Arnaud Goolaerts; Mathieu Lafargue; Yuanlin Song; Byron Miyazawa; Mehrdad Arjomandi; Michel Carlès; Jérémie Roux; Marybeth Howard; Dale A Parks; Karen E Iles; Jean-François Pittet
Journal:  Thorax       Date:  2011-07-18       Impact factor: 9.139

7.  CD44 deficiency is associated with increased bacterial clearance but enhanced lung inflammation during Gram-negative pneumonia.

Authors:  Gerritje J W van der Windt; Sandrine Florquin; Alex F de Vos; Cornelis van't Veer; Karla C S Queiroz; Jiurong Liang; Dianhua Jiang; Paul W Noble; Tom van der Poll
Journal:  Am J Pathol       Date:  2010-09-23       Impact factor: 4.307

8.  AMP-activated protein kinase activation by 5-aminoimidazole-4-carbox-amide-1-β-D-ribofuranoside (AICAR) reduces lipoteichoic acid-induced lung inflammation.

Authors:  Arie J Hoogendijk; Sandra S Pinhanços; Tom van der Poll; Catharina W Wieland
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

9.  PAI-1 inhibits neutrophil efferocytosis.

Authors:  Young-Jun Park; Gang Liu; Emmanuel F Lorne; Xia Zhao; Jing Wang; Yuko Tsuruta; Jaroslaw Zmijewski; Edward Abraham
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-08       Impact factor: 11.205

10.  Plasminogen activator inhibitor-1: a potential etiological role in livedoid vasculopathy.

Authors:  Yimeng Gao; Hongzhong Jin
Journal:  Int Wound J       Date:  2020-10-11       Impact factor: 3.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.